SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative healthcare products worldwide.
Become part of a challenging and vibrant environment. Be inspired to think large, grow, and succeed while positively impacting the world.
Advantages/Highlight: Increase ANC with the efficacy and safety of the first Filgrastim in PFS
Currently Marketed in: Philippines
Category: Oncology
Molecule/API/MOA: G-CSF
Advantages/Highlight: Insulin Delivery Devices injectable pharmaceutical products with thousands of satisfied patients around the world
Currently Marketed in: Emerging Markets
Category: Medical Device
Advantages/Highlight: High quality European human insulin with 20 years of experience confirms the products’ effectiveness, safety and stability
Currently Marketed in: Emerging Markets
Category: Endocrinology
Molecule/API/MOA: rh Insulin
DOWNLOAD BROCHURE FOR SCILIN® N
DOWNLOAD BROCHURE FOR SCILIN® R
DOWNLOAD BROCHURE FOR SCILIN® M30
Advantages/Highlight: A Swiss-made mistletoe containing product to address oncology support needs
Currently Marketed in: South Korea
Category: Oncology
Molecule/API/MOA: extracts of Viscum album (mistletoe)
Advantages/Highlight: Prolonged acting GnRH agonist with proven efficacy and safety data since 1986
Currently Marketed in: South Korea
Category: Endocrinology
Molecule/API/MOA: gonadotropin releasing hormone agonist
Advantages/Highlight: An innovative low level laser treatment for patients of Post-Mastectomy Lymphoedema
Currently Marketed in: South Korea
Category: Medical Device
Advantages/Highlight: Immune modulator to boost immune defense in immunocompromised patients
Currently Marketed in: South Korea
Category: Oncology
Molecule/API/MOA: Thymosin α1
Advantages/Highlight: European quality and ready-to-use rhGH for short stature correction
Currently Marketed in: Australia, Philippines, South Korea, Singapore, Vietnam, Malaysia, Hong Kong, Thailand
Category: Endocrinology
Molecule/API/MOA: rh Growth Hormone
Advantages/Highlight: Available in READY-TO-USE with advanced convenience
Currently Marketed in: Australia, Brunei, Hong Kong, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam
Category: Oncology
Molecule/API/MOA: Zoledronic Acid
ACCESS THE RMP INFO HERE (Only for Taiwan)
請點擊查看ZOMETA® 卓骨祂病人用藥安全指引（僅限臺灣地區使用）
Advantages/Highlight: To prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms
Currently Marketed in: South Korea
Category: Oncology
Molecule/API/MOA: sterile, nonpyrogenic solution of zinc, copper, manganese, chromium
Advantages/Highlight: Prevention of low levels of zinc
Currently Marketed in: South Korea
Category: Oncology
Molecule/API/MOA: ZINC sulfate hydrate
